An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients

Basit Öğe Kaydı
dc.contributor.authorErsoy, Mehmet A.
dc.contributor.authorNoyan, Aysin M.
dc.contributor.authorElbi, Hayriye
dc.date.accessioned2019-10-27T19:56:21Z
dc.date.available2019-10-27T19:56:21Z
dc.date.issued2008
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Depression is quite common among cancer patients. It has yet to be determined which antidepressant is the most effective in cancer patients with depression. Methods: The present study included 21 consecutive depressed oncology patients of whom 19 were followed up for 6 months. All patients initially received mirtazapine 15 mg/day and the dose was increased in the absence of significant treatment response and adverse effects. Results: Depressive symptoms diminished at the end of month 1 and this improvement was maintained for the remaining 23 weeks of the study. Mean 17-item Hamilton Rating Scale for Depression (HAM-D-17) scores fell significantly from 21.4 +/- 4.9 at baseline to 6.5 +/- 3.2 at the end of the first month of treatment (p < 0.001). Among the 19 patients who were followed up, five reported at least one adverse effect during treatment; however, the vast majority of these adverse effects were described as mild to moderate. Conclusion: This prospective, open-label study provides preliminary evidence regarding the efficacy, safety and tolerability of mirtazapine treatment in cancer patients with depression. Relatively low doses of mirtazapine appeared to be safe and effective for treating cancer patients undergoing radiotherapy and/or chemotherapy, and the reduction in the severity of depressive symptoms was maintained until the end of the 24-week treatment period.en_US
dc.identifier.doi10.2165/00044011-200828020-00005en_US
dc.identifier.endpage120en_US
dc.identifier.issn1173-2563
dc.identifier.issn1179-1918
dc.identifier.issue2en_US
dc.identifier.pmid18211119en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage113en_US
dc.identifier.urihttps://doi.org/10.2165/00044011-200828020-00005
dc.identifier.urihttps://hdl.handle.net/11454/40811
dc.identifier.volume28en_US
dc.identifier.wosWOS:000253244400005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAdis Int Ltden_US
dc.relation.ispartofClinical Drug Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleAn open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu